No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CAPR240816C10000
- 0.10
- 0.000.00%
15min DelayClose Jul 23 12:37 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume32 Open Interest10.00Strike Price0.00Turnover191.78%IV111.30%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1070Delta0.0782Gamma47.80Leverage Ratio-0.0089Theta0.0003Rho5.11Eff Leverage0.0023Vega
Intraday
- 5D
- Daily
News
Unveiling 6 Analyst Insights On Capricor Therapeutics
Capricor Therapeutics Analyst Ratings
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Capricor Therapeutics' CAP-1002 Shows Promise in DMD Treatment: Buy Rating Affirmed Following Positive Clinical Trials
Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer
Comments
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing
1
$Capricor Therapeutics(CAPR.US$
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics (NASDAQ: CAPR) announced a successful Type-B meeting with the FDA for their lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The FDA approved a rolling Biologics License Application (BLA) submission, set to begin in Q3 2024. The rolling BLA process could stream...
$Capricor Therapeutics(CAPR.US$ Capricor Therapeutics Inc - Remain on Track to Announce Topline Results From Phase 3 Hope-3 Pivotal Trial in Q4 of 2024
$Capricor Therapeutics(CAPR.US$ Reuters· just
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics Announces Positive 3-Year Efficacy Results From Hope-2 Open Label Extension Study of Cap-1002 in Duchenne Muscular Dystrophy
2
Read more